---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-409819"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2026-10-01T11:30:19+00:00"
generated_at: "2026-10-12T14:14:58.924935+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Kyntra Bio appoints Andrew Singer to board, Maykin Ho resigns; CEO Wettig signs new severance agreement

## Summary
- Andrew E. Singer, MBA was appointed as a Class III director and Audit Committee member effective October 1, 2026; his term expires in 2029.
- Maykin Ho, Ph.D. resigned from the board effective September 30, 2026 after serving since December 2018, including on the Audit Committee; no disagreement cited.
- CEO Thane Wettig entered a new Change in Control and Severance Agreement on September 30, 2026, with a three-year term ending October 2, 2029; no material changes to pay.
- Singer has 25+ years in biotech finance, led West Coast biotech investment banking at Credit Suisse, was Epizyme CFO, and advised on over $50 billion in transactions.
- Kyntra Bio common stock trades on Nasdaq under KYNB; it focuses on oncology and rare disease therapies.

## SEC filing metadata
- accession: 0001193125-26-409819
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2026-10-01T11:30:19+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000119312526409819/0001193125-26-409819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000119312526409819/kynb-20260930.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-409819
- JSON: https://secwatch.observer/filing/0001193125-26-409819.json
- Plain text: https://secwatch.observer/filing/0001193125-26-409819.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.